And, speaking of MannKind (MNKD)… ***excerpted from Issue #225 of Nate’s Notes (dated 10/11/13)*** Though I have done my best to help keep subscribers focused on the idea that the story at MannKind (or any development stage drug company, for that matter) … Continue reading →